Increased individual ownership through share exchange from Maas Biolab, LLC
One of NeuroVive’s largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas Biolab reducing its ownership of NeuroVive from 15.24% to 13.94%, and individual shareholders, including members of NeuroVive’s management, Board of Directors and co-founders, increasing their personal holdings in NeuroVive.“With this share exchange, Maas Biolab is continuing the strategy set in previous years of increasing the proportion of individual shareholdings in NeuroVive. Similar share